Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome

BACKGROUND: Rifaximin is a minimally absorbed antibiotic with high luminal activity, used to treat various gastrointestinal diseases. Although rifaximin has been proposed as first line treatment for small intestinal bacterial overgrowth (SIBO), few data are available regarding its efficacy in non-IB...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Boltin, Doron, Perets, Tsachi Tsadok, Shporn, Einav, Aizic, Shoshana, Levy, Sigal, Niv, Yaron, Dickman, Ram
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2014
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4201689/
https://ncbi.nlm.nih.gov/pubmed/25319626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12941-014-0049-x
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items